Actinium (225Ac) rhPSMA-10.1 clinical trials

ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

This study is testing a new radioactive drug called Actinium (225Ac) rhPSMA-10.1 for men with advanced prostate cancer that has spread. It aims to find a safe dose and see how well it works, especially for those who've already had a similar treatment.